Scios R&D Pipeline Led By Natrecor
US biopharmaceuticals company Scios has several products in clinicaltrials, but at the top of the list is Natrecor (nesiritide citrate; formerly human b-type natriuretic peptide) its treatment for acute congestive heart failure. The product has completed Phase III clinical trials, and filing for US approval is imminent, according to the company's annual report.
A marketing partnership is under discussion, and Phase II trials are underway for the use of Natrecor in post-operative hypertension.
Meantime, a New Drug Application has been submitted for the company's Fiblast (trafermin), for recalcitrant dermal wounds, in Japan, where it will be marketed by Kaken Pharmaceuticals. In cooperation with Wyeth-Ayerst, Scios has Fiblast in Phase II/III trials for stroke and in Phase II testing for peripheral vascular disease and coronary artery disease.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze